Grace Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Grace Therapeutics hat ein Gesamteigenkapital von $56.1M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $65.3M bzw. $9.2M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$15.17m
Eigenkapital	US$56.13m
Gesamtverbindlichkeiten	US$9.22m
Gesamtvermögen	US$65.35m

Jüngste Berichte zur Finanzlage

Recent updates

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Sep 02

We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Apr 20

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Nov 14

We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

May 10

Acasti Pharma GAAP EPS of -$0.10

Aug 11

Acasti inks deal for Grace Therapeutics, shares surge

May 07

Acasti Pharma issues clarification on trading activity

Dec 23

Acasti Pharma EPS in-line

Nov 16

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: GRCEDie kurzfristigen Aktiva des Unternehmens ($16.1M) übersteigen seine kurzfristigen Passiva ($2.7M).

Langfristige Verbindlichkeiten: GRCEDie kurzfristigen Vermögenswerte des Unternehmens ($16.1M) übersteigen seine langfristigen Verbindlichkeiten ($6.5M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: GRCE ist schuldenfrei.

Schulden abbauen: GRCE ist derzeit schuldenfrei, aber wir können keinen Vergleich mit dem Zeitraum vor 5 Jahren anstellen, da uns keine Daten für diesen Zeitraum vorliegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: GRCE auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: GRCE hat weniger als ein Jahr Liquidität, wenn der freie Cashflow weiterhin mit historischen Raten von 11.6% pro Jahr wächst.

Grace Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Acasti Pharma Announces 1-For-6 Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Continued Listing Requirement of the Nasdaq Capital Market

We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Recent updates

Acasti Pharma Inc. Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Acasti Pharma Inc., Annual General Meeting, Sep 30, 2024

Acasti Pharma Inc. Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-On Safety Trial

New major risk - Revenue and earnings growth

Acasti Pharma Inc. to Attend BIO International Convention 2024

We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

New major risk - Revenue and earnings growth

Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial

Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Acasti Pharma Inc. Announces Board Changes

Independent Chairman recently bought US$1.2m worth of stock

Acasti Pharma Inc. announced that it has received $7.499388 million in funding from S S Pharma Llc, Shore Pharma Llc

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2023

New minor risk - Share price stability

Acasti Pharma Announces 1-For-6 Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Continued Listing Requirement of the Nasdaq Capital Market

Acasti Pharma Inc. Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol

Acasti Pharma Inc. Announces Scientific Advisory Board Appointments

Forecast to breakeven in 2024

We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Second Quarter 2025

Acasti Pharma Inc. to Report Q3, 2023 Results on Feb 14, 2023

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma Inc. Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

Forecast to breakeven in 2024

High number of new and inexperienced directors

Acasti Pharma Inc. to Report Q2, 2023 Results on Nov 14, 2022

Acasti Pharma Inc. Announces Board Changes

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma GAAP EPS of -$0.10

Acasti Pharma Inc. to Report Q1, 2023 Results on Aug 11, 2022

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2022

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

Less than half of directors are independent

Less than half of directors are independent

Acasti Pharma Inc. Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, its Lead Drug Candidate for Treatment of Subarachnoid Hemorrhage

Acasti Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Insufficient new directors

Insufficient new directors

Acasti Pharma Inc. (TSXV:ACST) completed the acquisition of Grace Therapeutics, Inc.

Forecast breakeven pushed back to 2024

Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

Acasti Pharma Inc. (TSXV:ACST) entered into a definitive agreement to acquire Grace Therapeutics, Inc. for $71.4 million.

Acasti inks deal for Grace Therapeutics, shares surge

Earnings miss expectations

New 90-day high: US$0.90

New 90-day high: US$0.57

New 90-day high: US$0.43

Acasti Pharma issues clarification on trading activity

New 90-day high: US$0.29

Acasti Pharma Inc. Announces Resignation of Brian Groch as Chief Commercial Officer, Effective December 31, 2020

Acasti Pharma EPS in-line

Acasti Pharma Inc. Announces Executive Changes

New 90-day low - US$0.24

Acasti Pharma Inc. Auditor Raises 'Going Concern' Doubt

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen